Table 1.
Correlation between bcl-2 protein expression and clinicopathological parameters of gastric carcinomas
| n |
bcl-2 protein expression |
Positive rate (%) | ||||
| - | + | + + | + + + | |||
| Age (a) | ||||||
| ≤ 59 | 36 | 7 | 4 | 15 | 10 | 80.56 |
| ≥ 60 | 14 | 2 | 2 | 5 | 5 | 85.71 |
| Sex | ||||||
| M | 34 | 7 | 2 | 13 | 12 | 79.41 |
| F | 16 | 2 | 4 | 7 | 3 | 87.50 |
| Type | ||||||
| Intestinal | 28 | 2 | 3 | 13 | 10 | 92.86a |
| Diffuse | 22 | 7 | 3 | 7 | 5 | 68.18 |
| Grade of differentiation | ||||||
| Well/moderate | 18 | 7 | 1 | 5 | 5 | 61.11 |
| Poor | 22 | 1 | 4 | 12 | 5 | 95.45b |
| Mucoid | 10 | 1 | 1 | 3 | 5 | 90.00 |
| Tumor size | ||||||
| < 5 cm | 31 | 8 | 4 | 11 | 8 | 74.19 |
| ≥ 5 cm | 19 | 1 | 2 | 9 | 7 | 94.74 |
| Lymph-node metastasis | ||||||
| Negative | 21 | 4 | 2 | 9 | 6 | 80.95 |
| Positive | 29 | 5 | 4 | 11 | 9 | 82.76 |
| Serosal invasion | ||||||
| Absent | 25 | 7 | 3 | 9 | 6 | 72.00 |
| Present | 25 | 2 | 3 | 11 | 9 | 92.00 |
| Clinical stages | ||||||
| I and II | 32 | 6 | 5 | 12 | 9 | 81.25 |
| III and IV | 18 | 3 | 1 | 8 | 6 | 83.33 |
a
χ2 = 5.082, P < 0.05, vs diffuse-type gastric carcinoma;
b
χ2 = 7.298, P < 0.01, vs well/moderately differentiated gastric carcinoma.